Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim to build $65m US research facility

Will add new R&D operations to its US headquarters in Connecticut

Boehringer Ingelheim is expanding its R&D operations in the US with a new research and development facility.

The $65m facility will be located at the company's US headquarters in Ridgefield, Connecticut and when completed will handle production of active pharmaceutical ingredients used in early development activities.

It brings the total of Boehringer's investment in the US this year to $350m, adding to spending on projects such as a $42m new drug safety assessment building in Ridgefield and a $50m high containment operations facility in Columbus, Ohio.

J Martin Carroll, president and CEO of the company's US operations, said: “These are exciting projects; ones that increase Boehringer Ingelheim's research and development capabilities and reinforce our commitment to growth and innovation in the US.”

“Through these investments we are improving our ability to research, develop and manufacture the medicines of tomorrow and in doing so fulfilling our promise to bring more health to patients and their families.”

15th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics